Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00125034
Status:
COMPLETED
Last Update Posted:
2014-08-07
First Post:
2005-07-28
Brief Title:
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer mCRC
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Study Overview
Official Title:
Open Randomized Controlled Multicenter Phase II Study Comparing 5-FUFA Plus Oxaliplatin FOLFOX-4 Plus Cetuximab Versus 5-FUFA Plus Oxaliplatin FOLFOX-4 as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPUS
Brief Summary:
This is an open label randomized controlled multicenter phase II study comparing 5-FUFA oxaliplatin FOLFOX-4 cetuximab versus 5-FUFA oxaliplatin as first-line treatment for epidermal growth factor receptor EGFR-expressing mCRC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None